Literature DB >> 20399005

Comparative analysis of cerebrospinal fluid adenosine deaminase in tuberculous and non-tuberculous meningitis.

Ali Moghtaderi1, Abbasali Niazi, Roya Alavi-Naini, Saideh Yaghoobi, Behzad Narouie.   

Abstract

OBJECTIVE: To calculate cut-off point for the adenosine deaminase (ADA) activity in the CSF of patients with tuberculous meningitis (TBM). PATIENTS AND METHODS: The ADA assay was based on the automatic indirect method in which ADA catalyzes adenosine to inosine. ADA activity in the CSF was calculated based on ammonia liberated from adenosine and quantified spectrophotometrically. Arithmetic mean values and standard deviation of each variable were measured. Mann-Whitney U and Fisher exact tests were applied to compare continuous and dichotomous variables between tuberculous and non-tuberculous groups. A receiver operating characteristic curve was plotted to identify various cut-off points to determine the best level for ADA activity.
RESULTS: Totally 42 patients were enrolled into the study. The median of ADA activity in the TBM group was 22 and in the non-TBM group was 8.0. The mean CSF-ADA activity was found to be significantly higher in TBM group (23.05+/-13.1IU/L) than in the CSF from non-TBM patients (9.39+/-5.18IU/L). The highest accuracy is at the cut-off value of 10.5IU/L. The sensitivity and specificity of the test at this cut-off to differentiate TBM from non-tuberculous meningitis is 81% and 86% respectively.
CONCLUSION: Considering that a high positive value of ADA activity cannot confirm TBM, however, in suspected patients it may lead the physician to treat patient earlier before the confirmatory diagnostic reports will be received. The suggested cut-off value in this pilot study is 10.5IU/L with high sensitivity and specificity. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399005     DOI: 10.1016/j.clineuro.2009.12.006

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  8 in total

1.  Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis.

Authors:  Batool Zamani; Raika Jamali; Hassan Ehteram
Journal:  Rheumatol Int       Date:  2010-08-19       Impact factor: 2.631

2.  Prospective Analysis of 55 Cases of Tuberculosis Meningitis (TBM) in North India.

Authors:  Harsimran Kaur; Kusum Sharma; Manish Modi; Aman Sharma; Satyawati Rana; Niranjan Khandelwal; Sudesh Prabhakar; Subhash Varma
Journal:  J Clin Diagn Res       Date:  2015-01-01

3.  Serum adenosine deaminase may predict disease activity in rheumatoid arthritis.

Authors:  Batool Zamani; Raika Jamali; Arsia Jamali
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

4.  Predictive Role of ADA in Bronchoalveolar Lavage Fluid in Making the Diagnosis of Pulmonary Tuberculosis.

Authors:  Fariba Binesh; Abolhassan Halvani
Journal:  Pulm Med       Date:  2013-12-24

5.  Tuberculous Meningitis-Mimicking Varicella-Zoster Meningitis.

Authors:  Sun In Hong; Taeeun Kim; Jiwon Jung; Se Yoon Park; Yong Pil Chong; Sang Oh Lee; Sang Ho Choi; Yang Soo Kim; Jun Hee Woo; Sang Ahm Lee; Sung Han Kim
Journal:  Infect Chemother       Date:  2017-06

Review 6.  Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches.

Authors:  Charles M Manyelo; Regan S Solomons; Gerhard Walzl; Novel N Chegou
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

7.  CSF ADA Determination in Early Diagnosis of Tuberculous Meningitis in HIV-Infected Patients.

Authors:  Gopal Chandra Ghosh; Brijesh Sharma; B B Gupta
Journal:  Scientifica (Cairo)       Date:  2016-04-06

8.  Diagnostic accuracy of cerebrospinal fluid adenosine deaminase in detecting Tuberculous Meningitis.

Authors:  Aamir Habib; Zulfiqar Ali Amin; Syed Hassan Raza; Sobia Aamir
Journal:  Pak J Med Sci       Date:  2018 Sep-Oct       Impact factor: 1.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.